MX2009005413A - Formas cristalinas del acido zoledronico. - Google Patents
Formas cristalinas del acido zoledronico.Info
- Publication number
- MX2009005413A MX2009005413A MX2009005413A MX2009005413A MX2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A MX 2009005413 A MX2009005413 A MX 2009005413A
- Authority
- MX
- Mexico
- Prior art keywords
- zoledronic acid
- crystalline forms
- crystalline form
- crystalline
- free acid
- Prior art date
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004276 zoledronic acid Drugs 0.000 title abstract 6
- 239000002253 acid Substances 0.000 abstract 4
- 150000004682 monohydrates Chemical class 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 2
- 238000002405 diagnostic procedure Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se refiere a nuevas formas cristalinas de sales de ácido zoledrónico de baja solubilidad en agua, al proceso para la preparación de estas formas cristalinas, a composiciones que contienen estas formas cristalinas, y al uso de estas formas cristalinas en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos. La invención se refiere a la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, al proceso para la preparación de la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, a composiciones que contienen la forma cristalina del monohidrato de ácido libre del ácido zoledrónico, y al uso de la forma cristalina del monohidrato de ácido libre del ácido zoledrónico en métodos de diagnóstico o en el tratamiento terapéutico de animales de sangre caliente, en especial seres humanos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06124850A EP1925621A1 (en) | 2006-11-27 | 2006-11-27 | Crystalline forms of zoledronic acid |
| PCT/EP2007/010255 WO2008064849A1 (en) | 2006-11-27 | 2007-11-26 | Crystalline forms of zoledronic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009005413A true MX2009005413A (es) | 2009-06-01 |
Family
ID=37909616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009005413A MX2009005413A (es) | 2006-11-27 | 2007-11-26 | Formas cristalinas del acido zoledronico. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100056481A1 (es) |
| EP (2) | EP1925621A1 (es) |
| JP (1) | JP2010510970A (es) |
| KR (1) | KR20090083407A (es) |
| CN (1) | CN101535323A (es) |
| AR (1) | AR063923A1 (es) |
| AU (1) | AU2007324833A1 (es) |
| BR (1) | BRPI0719567A2 (es) |
| CA (1) | CA2670638A1 (es) |
| CL (1) | CL2007003389A1 (es) |
| MX (1) | MX2009005413A (es) |
| PE (1) | PE20081391A1 (es) |
| RU (1) | RU2009123936A (es) |
| TW (1) | TW200829598A (es) |
| WO (1) | WO2008064849A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2407746C2 (ru) * | 2008-09-29 | 2010-12-27 | ЗАО "Фарм-Синтез" | Радиофармацевтическое средство для диагностики и лечения (терапии) костных поражений скелета и способ его получения |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| EP2458996B1 (en) | 2009-07-31 | 2016-09-07 | Thar Pharmaceuticals, Inc. | Novel oral forms of a phosphonic acid derivative |
| ES2650665T3 (es) | 2009-07-31 | 2018-01-19 | Grünenthal GmbH | Método de cristalización y biodisponibilidad |
| ES2537216T3 (es) * | 2009-09-01 | 2015-06-03 | Duke University | Composiciones de bisfosfonato y métodos para tratar la insuficiencia cardíaca |
| BR112012026098A2 (pt) | 2010-04-16 | 2016-11-22 | Novartis Ag | métodos e composições para melhorar a osseointegração de implante. |
| WO2012071517A2 (en) | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| JP6492321B2 (ja) * | 2015-03-23 | 2019-04-03 | 株式会社大阪合成有機化学研究所 | ［１−ヒドロキシ−２−（イミダゾ［１，２−ａ］ピリジン−３−イル）エチリデン］ビスホスホン酸一水和物の製造方法 |
| EP3455229B1 (en) | 2016-05-13 | 2021-03-24 | Thar Pharma LLC | Novel crystalline forms |
| WO2017208070A1 (en) | 2016-05-31 | 2017-12-07 | Grünenthal GmbH | Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis |
| CN106749405B (zh) * | 2016-12-29 | 2019-07-16 | 江苏省原子医学研究所 | 一种咪唑杂环类双膦酸化合物及其制备方法、应用 |
| JP2021504315A (ja) | 2017-11-21 | 2021-02-15 | ルジェニクス，インコーポレーテッド | 多形及びその使用 |
| CN110551152A (zh) * | 2018-05-31 | 2019-12-10 | 四川科伦药物研究院有限公司 | 唑来膦酸一水合物及无水物晶型制备方法 |
| JP2022527606A (ja) * | 2019-04-11 | 2022-06-02 | シァメン・イノヴァックス・バイオテック・カンパニー・リミテッド | ゾレドロン酸亜鉛マイクロ／ナノ粒子アジュバントの作製及びワクチンアジュバントとしてのその使用 |
| HUE067466T2 (hu) * | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| CN112778365A (zh) * | 2020-12-30 | 2021-05-11 | 华南理工大学 | 一种唑来膦酸钙配合物及其制备方法 |
| CN112646193A (zh) * | 2020-12-30 | 2021-04-13 | 华南理工大学 | 一种块状双膦酸钙配合物及其制备方法 |
| CN112724174A (zh) * | 2020-12-30 | 2021-04-30 | 华南理工大学 | 一种薄片状双膦酸钙配合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4244422A1 (de) * | 1992-12-29 | 1994-06-30 | Boehringer Mannheim Gmbh | Schwerlösliche Zink- und Magnesiumsalze von 1,1-Bisphosphonsäuren, ihre Herstellung und Verwendung als Arzneimittel |
| US20040097468A1 (en) * | 2002-11-20 | 2004-05-20 | Wimalawansa Sunil J. | Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment |
| EP1612212A1 (en) * | 2003-07-03 | 2006-01-04 | Teva Pharmaceutical Industries Ltd | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| US20060178439A1 (en) * | 2005-01-04 | 2006-08-10 | Mohakhud Pradeep K | Crystalline form of zoledronic acid |
| AR054673A1 (es) * | 2005-07-28 | 2007-07-11 | Gador Sa | Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende |
| US20080255366A1 (en) * | 2005-09-12 | 2008-10-16 | Dr. Reddy's Laboratories Limited | Crystalline Trihydrate of Zoledronic Acid |
| WO2007125521A2 (en) * | 2006-05-02 | 2007-11-08 | Ranbaxy Laboratories Limited | Polymorphic form of zoledronic acid and processes for their preparation |
-
2006
- 2006-11-27 EP EP06124850A patent/EP1925621A1/en not_active Ceased
-
2007
- 2007-11-23 AR ARP070105215A patent/AR063923A1/es unknown
- 2007-11-23 PE PE2007001630A patent/PE20081391A1/es not_active Application Discontinuation
- 2007-11-26 EP EP07846821A patent/EP2089404A1/en not_active Withdrawn
- 2007-11-26 CN CNA2007800419850A patent/CN101535323A/zh active Pending
- 2007-11-26 US US12/515,742 patent/US20100056481A1/en not_active Abandoned
- 2007-11-26 CA CA002670638A patent/CA2670638A1/en not_active Abandoned
- 2007-11-26 BR BRPI0719567-2A patent/BRPI0719567A2/pt not_active Application Discontinuation
- 2007-11-26 JP JP2009537559A patent/JP2010510970A/ja active Pending
- 2007-11-26 TW TW096144824A patent/TW200829598A/zh unknown
- 2007-11-26 WO PCT/EP2007/010255 patent/WO2008064849A1/en active Application Filing
- 2007-11-26 CL CL200703389A patent/CL2007003389A1/es unknown
- 2007-11-26 KR KR1020097010727A patent/KR20090083407A/ko not_active Application Discontinuation
- 2007-11-26 RU RU2009123936/04A patent/RU2009123936A/ru not_active Application Discontinuation
- 2007-11-26 AU AU2007324833A patent/AU2007324833A1/en not_active Abandoned
- 2007-11-26 MX MX2009005413A patent/MX2009005413A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2670638A1 (en) | 2008-06-05 |
| TW200829598A (en) | 2008-07-16 |
| EP2089404A1 (en) | 2009-08-19 |
| BRPI0719567A2 (pt) | 2013-12-10 |
| JP2010510970A (ja) | 2010-04-08 |
| US20100056481A1 (en) | 2010-03-04 |
| RU2009123936A (ru) | 2011-01-10 |
| CL2007003389A1 (es) | 2008-06-27 |
| WO2008064849A1 (en) | 2008-06-05 |
| PE20081391A1 (es) | 2008-11-14 |
| EP1925621A1 (en) | 2008-05-28 |
| AU2007324833A1 (en) | 2008-06-05 |
| KR20090083407A (ko) | 2009-08-03 |
| CN101535323A (zh) | 2009-09-16 |
| AR063923A1 (es) | 2009-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009005413A (es) | Formas cristalinas del acido zoledronico. | |
| MY164274A (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| EA201101243A1 (ru) | 3h-имидазо[4,5-c]пиридин-6-карбоксамиды в качестве противовоспалительных средств | |
| MY166653A (en) | Derivatives of 1-amino-2-cyclobutylethylboronic acid | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| TW200606162A (en) | Pyrazolopyridine derivatives | |
| MX2009008253A (es) | Derivados de 2-aminopiridina utiles como inhibidores de cinasa. | |
| MY171577A (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| MX2009012066A (es) | Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k. | |
| WO2010011772A3 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
| PH12012502568A1 (en) | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts | |
| EP2418945A4 (en) | Mineral salt-sulfuric acid compositions and methods for their use | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX2009007265A (es) | Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion. | |
| BRPI0911678B8 (pt) | maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central | |
| WO2010036567A3 (en) | Harmine compounds for promoting bone growth | |
| WO2010022201A3 (en) | Folinic acid derivatives for promoting bone growth | |
| MX2011008074A (es) | Macrolido anti-inflamatorio. | |
| TW200628474A (en) | Organic compounds | |
| GB0609897D0 (en) | Compounds | |
| SMT201300112B (it) | Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene | |
| MY148254A (en) | Tartrate derivatives for use as coagulation factor ixa inhibitors | |
| MY182553A (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| TW200833708A (en) | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | |
| MY160005A (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |